- Home
- NBR vs AVBP Comparison
NBR vs AVBP Comparison
Compare NBR & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBR
- AVBP
- Stock Information
- Founded
- NBR 1952
- AVBP 2021
- Country
- NBR Bermuda
- AVBP United States
- Employees
- NBR N/A
- AVBP N/A
- Industry
- NBR Oil & Gas Production
- AVBP
- Sector
- NBR Energy
- AVBP
- Exchange
- NBR Nasdaq
- AVBP NYSE
- Market Cap
- NBR 633.5M
- AVBP 617.4M
- IPO Year
- NBR N/A
- AVBP 2024
- Fundamental
- Price
- NBR $42.82
- AVBP $18.00
- Analyst Decision
- NBR Hold
- AVBP Strong Buy
- Analyst Count
- NBR 7
- AVBP 6
- Target Price
- NBR $73.33
- AVBP $39.00
- AVG Volume (30 Days)
- NBR 483.9K
- AVBP 193.7K
- Earning Date
- NBR 04-23-2025
- AVBP 03-03-2025
- Dividend Yield
- NBR N/A
- AVBP N/A
- EPS Growth
- NBR N/A
- AVBP N/A
- EPS
- NBR N/A
- AVBP N/A
- Revenue
- NBR $2,930,126,000.00
- AVBP N/A
- Revenue This Year
- NBR $13.54
- AVBP $63.13
- Revenue Next Year
- NBR $8.39
- AVBP N/A
- P/E Ratio
- NBR N/A
- AVBP N/A
- Revenue Growth
- NBR N/A
- AVBP N/A
- 52 Week Low
- NBR $34.42
- AVBP $14.35
- 52 Week High
- NBR $105.96
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- NBR 46.99
- AVBP 27.17
- Support Level
- NBR $40.08
- AVBP $17.54
- Resistance Level
- NBR $45.69
- AVBP $19.04
- Average True Range (ATR)
- NBR 2.42
- AVBP 1.02
- MACD
- NBR 0.46
- AVBP -0.01
- Stochastic Oscillator
- NBR 48.84
- AVBP 9.91
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.